Research News & Analysis
Evidence-based research guides, scientific articles, and educational resources on BPC-157, Semaglutide, Retatrutide, metabolic research, tissue repair and more. Updated regularly for laboratory and independent research.
Looking for protocols or compound reference?
This page is news, regulatory coverage and analysis. Reconstitution and blend protocols live in the guide corpus; per-compound mechanism, specifications and storage live in the reference library.
All Articles
MOTS-c FDA Compounding 2026: Mitochondrial Peptide Research Guide
MOTS-c FDA compounding 2026 status affects research access to this 16-amino-acid mitochondrial peptide. Learn what the bulk list means for labs.
Thymosin Alpha-1 Research 2026: Immunity Peptide Study Guide
Thymosin Alpha-1 research covers a 28-amino acid immunomodulatory peptide with documented T-cell activation properties. This guide reviews mechanisms, FDA compounding context, and study parameters for 2026.
FDA Peptide Compounding Vote 2026: 7 Peptides Added to Bulk List
FDA peptide compounding vote 2026 result: PCAC recommends 7 peptides for the 503B bulk substances list. Full breakdown of compounds and regulatory implications.
Semaglutide vs Tirzepatide Discontinuation Research: Comparative Rebound Data 2026
Semaglutide vs tirzepatide discontinuation research reveals distinct rebound patterns, persistence rates, and reinitiation behaviors. 2025-2026 studies compare weight regain, metabolic reversal, and implications for high-purity research peptide protocols.
CagriSema vs Retatrutide: ADA 2026 Clinical Comparison Research
CagriSema retatrutide comparison reveals two distinct dual-agonist mechanisms targeting obesity. This guide covers receptor profiles, trial data, and research applications for 2026.
Injectable Peptide Regulation Gap 2026: JAMA Research Analysis
Injectable peptide regulation gaps identified in 2026 JAMA research reveal systemic oversight failures affecting lab-grade compound quality, purity verification, and research integrity.
Epitalon & Semax: Preclinical Neuroprotective Peptide Studies
Epitalon and Semax neuroprotective peptides show distinct bioregulatory mechanisms in preclinical models. This guide reviews published research on telomerase activation, BDNF upregulation, and receptor binding kinetics.
Retatrutide Phase 3 Trials 2026: What Researchers Need to Know
Retatrutide phase 3 trials in 2026 advance a triple incretin agonist through late-stage evaluation. This guide covers trial design, mechanisms, and research compound sourcing.
Melanotan-II Peptide Research: Abnormal Mole Development Studies
Melanotan-II peptide research reveals associations between MC1R activation and nevus development. Explore key studies, mechanisms, and safety data for researchers.
GLP-1 Cancer Research 2026: Breast & Prostate Tumor Slowdown Studies
GLP-1 cancer research in 2026 reveals that receptor agonists may slow tumor proliferation in breast and prostate models. This guide reviews the mechanisms, study data, and research implications.
Selank Research Peptide: Anxiolytic Mechanism & Lab Protocols 2026
Selank research peptide is a synthetic anxiolytic analog of Tuftsin that upregulates BDNF and modulates GABAergic transmission. This 2026 guide details molecular targets, intranasal dosing protocols, and lab-grade purity requirements for in-vitro and animal studies.
AI Peptide Antibiotic Optimization: 2026 Research Protocols & Data
AI peptide antibiotic optimization is reshaping 2026 antimicrobial research. Discover machine-learning peptide design, lab-validated assays, and sourcing standards for high-purity research peptides.
FDA Peptide Ban Reversal 2026: What Researchers Must Know Now
FDA peptide ban reversal could reopen 503B bulk list to cosmetic peptides by Q2 2026, restoring GHK-Cu, Argireline, and Matrixyl for dermatology research.
Antimicrobial Peptides in Cancer Research 2026: Mechanisms & Trials
Antimicrobial peptides cancer research shows LL-37 and defensins trigger immunogenic cell death, inhibit angiogenesis, and enhance checkpoint blockade in 2026 pre-clinical models.
FDA Approves Lilly's Foundayo: Research Implications
FDA approval of Lilly's Foundayo redefines GLP-1 research standards. This guide details molecular specs, receptor pharmacology, and procurement of research-grade analogs.
Amazon Bacteriostatic Water Ban: Peptide Reconstitution Alternatives
Amazon delisted all bacteriostatic water listings in Q2 2025, disrupting peptide reconstitution workflows for research labs. This guide reviews compliant sourcing, purity specifications, and sterile diluent alternatives validated for in-vitro peptide work.
FDA Peptide Restriction Lift: 2026
FDA peptide restriction lift expected in 2026 will reclassify several research peptides from Category II to Category I, expanding laboratory access to high-purity compounds for in-vitro and animal studies.
Novel Protein Reading Method in Bioengineering | Implications for Peptide Research
Discover the new protein reading method shaping peptide research. Learn its impact, applications, and how to source high-purity peptides for your studies.
ENA101 Bispecific Peptide: DARKFOX-Targeting T Cell Engager Research
ENA101 bispecific peptide is a DARKFOX-targeting T cell engager designed for solid tumor immunotherapy research, bridging CD3-positive T cells to tumor antigens with high specificity.
FDA Peptide Ban List 2025: What Research Labs Need to Know
FDA peptide ban list 2025 explained: which compounds are restricted, why compounding rules changed, and how research labs can maintain compliant procurement.
Novo Nordisk Triple Agonist Obesity Peptide: GGG Tri-Agonist
Triple agonist obesity peptide research targets GIP, GLP-1, and glucagon receptors simultaneously. This guide covers mechanisms, study data, and sourcing standards for researchers.
A Comprehensive Research Guide: Getting Started with Peptides
Discover the essentials of peptide research, including types, applications, quality assurance, and purity testing methods for reliable and reproducible results.